Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

On Super Bowl Sunday, many tuning into the big game saw a controversial ad from the telehealth company Hims & Hers. The ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...